SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi announced it has become the first U.S. national bank to go live with stablecoin settlement across Mastercard's global payments network, using its SoFiUSD stablecoin to settle card transactions on-chain, with shares moving higher in premarket trading. Bulls are calling it a major milestone and potential short-squeeze fuel given heavy short interest, while skeptics expect the pop to fade at the open and question how much near-term revenue it actually adds, citing the stock's history of selling off on good news.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is drawing heavy attention after the company reported positive topline results from a VK2735 weight-loss maintenance study. Traders cite roughly 97% weight-loss maintenance within the trial's 5% threshold, weight loss matching Eli Lilly's retatrutide at the 21- and 33-week marks, and what they describe as a best-in-industry side-effect profile. The company characterized the dose-ranging data as demonstrating the potential viability of novel extended-dosing approaches for maintenance following incretin-based induction.

The reaction is split. Bulls argue the results confirm a best-in-class obesity asset, point to a market cap of roughly $4B as leaving the stock undervalued, and see heavy short interest  one trader citing about 22 million shares short  as fuel for a squeeze. Skeptics counter that maintenance patients almost always regain some weight, that low oral bioavailability limits the oral formulation's dosing, and that other positive obesity readouts have produced lackluster stock reactions; self-identified shorts expect the move to fade. A competing explanation ties the move more to Novo Nordisk's turmoil than to the data itself.

M&A speculation is running alongside the results: traders are floating a Novo Nordisk partnership or a large buyout of Viking after Novo's CEO said the company is 'quite interested' in deals that fill pipeline gaps and that its balance sheet could support larger acquisitions than typical bolt-ons, though others read Novo's messaging as a signal it will not pursue Viking. Many participants stress that the Phase 3 VK2735 readouts  from a program with roughly 5,500 patients enrolled  remain the decisive catalyst.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending ahead of its upcoming earnings report as investors react to a new partnership with Sift to stream sensor data for Physical AI systems. Community sentiment is largely bullish, with traders emphasizing QNX's role in the software-defined vehicle and robotics sectors, though some maintain a cautious stance awaiting a blowout performance to confirm a sustained share price re-rating.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft's formalization of AI safety rules is driving the conversation. The company has unveiled a draft AI code of conduct that would require its future in-house models to accept correction, never resist shutdown, and communicate intelligibly with humans  a move traders frame as part of a broader industry debate over slowing AI development, alongside commentary from Meta and OpenAI. Reaction is split: some see the codification of human-control requirements at the model level as a positive for enterprise trust, while a vocal portion of the community is skeptical, speculating the safety push is a cover for cost concerns rather than genuine ethics. That skepticism feeds a parallel spending debate  traders point to Foundry's substantial losses, claims that AI capex is being funded through borrowing rather than cash flow, and data-center energy constraints as risks to the AI growth narrative. The debate is also surfacing in analyst actions, with Redburn raising its target to $440 and Citizens reiterating a $550 Market Outperform explicitly on the AI safety debate, though some traders argue the stock won't re-rate until earnings momentum and free-cash-flow growth justify the upgrades.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify's Q2 earnings beat is dominating the conversation, with traders citing revenue of $3.58B versus roughly $3.44B consensus (34% growth), GMV of $115.57B, and stronger-than-expected Q3 guidance that they say eased fears of AI-driven disruption  the resulting surge marked the stock's biggest intraday gain since November 2024. The dominant debate is whether AI helps or kills the business: bulls point to Bernstein's outperform initiation with a $160 price target and argue AI-disintermediation risk is overdone, while bears are openly shorting the name as a "dying company," warning AI website-building tools will erode Shopify's moat and that the ~$160B market cap leaves little room for error; short-squeeze chatter is circulating amid the fight. Skeptics also question earnings quality, speculating the beat leaned on buybacks and unrealized gains rather than core operations, and traders are split on whether the move holds, watching technical levels like the 21-day moving average for confirmation.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly gained attention as CEO Dave Ricks said Foundayo now captures roughly one-third of new GLP-1 pill starts, with the company breaking ground on a new Houston plant to expand oral obesity-drug capacity amid the intensifying oral battle with Novo Nordisk's Wegovy pill. The community split over the share data, with bulls highlighting Foundayo's rapid gains in new starts and skeptics noting the Wegovy pill still leads in weekly prescriptions.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is drawing heavy retail attention after CEO Ryan Cohen disclosed another sizable open-market purchase of more than a million shares in a regulatory filing, extending a string of insider buys including additional purchases by directors, and sending shares modestly higher. Traders are split on the implications, with squeeze hopes and Roaring Kitty speculation running up against frustration that the stock's reaction has been muted despite the insider buying.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Xanadu Quantum Technologies is experiencing significant downward pressure as traders express concerns over the upcoming September share lockup expiration and potential dilution, which many believe will lead to further volatility. While some participants highlight recent collaborations with AMD and ASML as long-term catalysts, the broader sentiment remains cautious due to the company's limited revenue and ongoing cash burn.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD's steep climb to record highs and its entry into the $1 trillion market-cap conversation  with traders celebrating it as the newest trillion-dollar chip name alongside Nvidia, Broadcom, and Micron  is the dominant topic. Posts repeatedly describe a parabolic run, citing gains of more than $170 per share, surging bullish sentiment, and a short squeeze that has 'short sellers getting wrecked,' fueling warnings not to short and FOMO-driven buying. Traders attribute the rally to AI chip demand, casting AMD as the No. 2 AI GPU supplier behind Nvidia; some point to the OpenAI partnership and its penny-priced warrants, while others tie momentum to chip-demand bets around Meta's Muse AI and the broader AI chip rally that has lifted Nvidia, Broadcom, and TSMC. The loudest debate is momentum versus exuberance: bulls argue the AI story is far from over, while skeptics call the market a casino, question a valuation they see as far richer than chip peers, argue the run lacks major fresh news beyond price hikes, and discuss locking in profits. Claims that executives are dumping shares reflect individual trader accusations, not confirmed developments.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global's rally to 52-week highs and a closely watched fight around the $30 level are dominating the conversation, with bulls citing fundamentals to justify the move and taunting short sellers. Traders point to the company's Q2 balance sheet  roughly $1.485 billion in cash and short-term investments and $545 million in first-half operating cash flow  plus a guidance raise that management attributed to core-business strength. Commentary from management appearances at Goldman Sachs and Citi conferences, covering accelerating AI platform adoption and a diversified industry-vertical mix, added to the bullish case. Sentiment skews heavily long: many frame Q3 earnings and the ZETA Live event as potential catalysts, celebrate a CalSTRS disclosure that traders describe as a sharply increased pension stake, and dismiss a Class A share offering (about 818,000 shares, roughly $25 million issued over several fiscal years) as immaterial. Skeptical voices reference the Culper Research short report and options-expiry dynamics, and some bulls hedge with puts or wait for dips, but bearish takes are largely drowned out.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate 

Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.

Should You Invest in the VanEck Biotech ETF (BBH)?

The Zacks Analyst Blog Highlights Amgen, Crinetics, FBT, BBH and BBP

Biotech ETFs are riding innovation, obesity drug growth and M&A, offering diversified exposure to the sector???s powerful rally.

Bet on These Biotech ETFs as Innovation Drives Market-Beating Growth 

 Biotech ETFs are riding a powerful rally fueled by innovation, obesity drugs and M&A, with three funds offering diversified exposure to growth.

Healthcare ETFs Are Looking Up: Here's Why 

Healthcare ETFs are hitting 52-week highs as earnings improve, dealmaking accelerates, FDA approvals stay strong and investors seek defensive growth.

Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market

GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.

GILD Stock Jumps After Winning Accelerated FDA Approval For HDV Treatment 

Equity

 U.S. Food and Drug Administration (FDA) approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus.

The Zacks Analyst Blog Highlights IBB, XBI, BBH and GNOM

IBB and peers are gaining traction as AI transforms biotech, boosting drug discovery, trials and growth prospects across diversified ETF portfolios.

VanEck ETF Trust - VanEck Biotech ETF

Neutral Sentiment

Rising interest rates

Surging bond yields

Oil/energy volatility

Trump/political risk

U.S. investors are navigating a stacked macro backdrop, with the Federal Reserve hiking rates for the first time since July 2023, the 10-year Treasury yield hitting 5.00% - its highest level since 2007 - and oil prices swinging between $94 and $105 a barrel amid the ongoing U.S.-Iran conflict and Saudi pipeline disruptions. What's the biggest risk to your portfolio right now? Vote and explain your reasoning in the comments.

With the Fed hiking rates for the first time since 2023, the 10-year Treasury yield near 5%, and oil prices swinging on the U.S.-Iran conflict, what&#39;s the biggest risk to your portfolio right now?

Stocktwits

With the Fed hiking rates for the first time since 2023, the 10-year Treasury yield near 5%, and oil prices swinging on the U.S.-Iran conflict, what's the biggest risk to your portfolio right now?

Feed

News

Sentiment

Fundamentals

Info

BBH VanEck Biotech ETF

Fundamentals

Latest BBH News